Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress Calistoga Pharmaceuticals, Inc., the leader in the advancement of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory illnesses, today presented preclinical and medical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain relaxes pelvic muscles . Results from the interim evaluation of the ongoing Stage 1 scientific trial demonstrate clinical advantage in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma , mantle cell lymphoma , and chronic lymphocytic leukemia .
as result of stress
Caliper launches new LabChip Dx program for clinical research laboratories Caliper Lifestyle Sciences, Inc. Today announced the launch of Caliper’s brand-new, innovative LabChip Dx system for use by scientific analysis laboratories developing molecular diagnostic lab tests. The LabChip Dx system is now available in major markets all over the world and allows simultaneous analysis as high as ten different analytes in one sample. The LabChip Dx program is the latest next era product platform utilizing Caliper’s microfluidic technology and intellectual real estate, and delivers ease of use combined with rapid, accurate, and cost-effective testing. It is also capable of analyzing many multiplex samples using minimal sample quantity and avoids the necessity to additional purify or dilute diagnostic PCR products.